Trial Information

Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study

215 women with breast cancer were evaluated for fertility preservation before chemotherapy.
Of those, 79 elected to undergo controlled ovarian stimulation (COH) with letrozole and
gonadotropins for embryo or oocyte cryopreservation. The 136 patients who declined served as
controls.There were no significant differences between the study and control groups
regarding age at diagnosis, breast cancer prognostic parameters (tumor size, grade, number
of positive lymph nodes, estrogen receptor status, her2-neu overexpression and vascular
space invasion), and chemotherapy regimens. There was no difference between the two groups
in the projected 10 year relapse, breast cancer specific mortality or overall mortality.
There were 3 recurrences or contralateral breast cancers (2 distant, 1 locoregional) in the
letrozole group, and 11 in the control group (9 distant, 1 locoregional, 1 contralateral
breast).

Comparison; breast cancer patients that underwent ovarian stimulation with
letrozole+gonadotropins and those who declined ovarian stimulation.